Table 1 Clinical characteristics of the sample
From: Outcome measures and treatment effectiveness in late onset myasthenia gravis
Type of MG (n° pts) | OCULAR (36) | EOMG (40) | LOMG (72) | THYMOMA (25) | SN (21) | ANTI-MUSK (14) | Total (208) | |
|---|---|---|---|---|---|---|---|---|
sex Female/male | 14 /22 | 36 /4 | 17 /55 | 15 /10 | 12 /9 | 10 /4 | 104 /104 | |
Average age (years) | 68,3 ± 10.9 | 44,2 ± 10,7 | 73,5 ± 8,5 | 59,4 ± 14,4 | 58,3 ± 10,9 | 57,4 ± 8,9 | 62,6 ± 15,0 | |
Average age at onset (years) | 60,8 ± 15,3 | 28,9 ± 11,5 | 66,8,1 ± 9,3 | 45,0 ± 16,3 | 48,2 ± 16,5 | 44,8 ± 16,8 | 52,3 ± 19,4 | |
Disease duration | 7,4 ± 7,7 | 16,0 ± 11,3 | 6,7 ± 4,0 | 14,4 ± 9,4 | 10,1 ± 9,2 | 12,6 ± 12,5 | 10,3 ± 9,1 | |
Severity at Onset (MGFA) | I | 36 | 1 (2,5%) | 23 (31,9%) | 2 | 10 | 0 | 72 (34,6%) |
IIA/IIB | 0 | 11 (27,5%)/14 (35%) | 11 (15,3%)/26 (36,1%) | 5/12 | 5/12 | 2 /9 | 34 (16,3%)/65 (31,2%) | |
IIIA/IIIB | 0 | 1 (2,5%)/11 (27,5%) | 2 (2,8%)/10 (13,9%) | 1/5 | 1/5 | 1/1 | 6 (2,9%)/25 (12,1%) | |
IVA/IVB | 0 | 1 (2,5%)/1 (2,5%) | 0 | 0 | 0 | 0/1 | 1 (0,5%)/2 (1%) | |
Worst severity during the course of the disease (MGFA) | I | 36 | 0 | 0 | 0 | 0 | 0 | 36 (17,3%) |
IIA/IIB | 0 | 5 (12,5%)/11 (27,5%) | 8 (11,1%)/25 (34,7%) | 4/4 | 7/7 | 1/4 | 25 (12,1%)/51 (24,5) | |
IIIA/IIIB | 0 | 2 (5%)/13 (32,5%) | 3 (4,2%)/24 (33,3%) | 2/11 | 1/5 | 0/4 | 8 (3,8%)/57 (27,4%) | |
IVA/IVB | 0 | 2 (5%)/3 (7,5%) | 2 (2,8%)/7 (9,7%) | 0/3 | 0/1 | 0/3 | 4 (1,9%)/17 (8,2%) | |
V | 0 | 4 (10%) | 3 (4,2%) | 1 | 0 | 2 | 10 (4,8%) | |
thymic hyperplasia (histology/thymectomized) | 2/3 | 34/34 | 4/4 | 0/25 | 4/5 | 0/1 | 44/ 72 | |
N. of comorbidity | 0 | 9 (25%) | 20 (50%) | 7 (9,7%) | 8 (32%) | 3 (14,3%) | 3 (21,4%) | 50 |
1–2 | 24 (66,7%) | 14 (35%) | 39 (54,2%) | 10 (40%) | 17 (80,9%) | 9 (64,3%) | 113 | |
3–4 | 3 (8,3%) | 6 (15%) | 22 (30,6%) | 6 (24%) | 1 (4,8%) | 2 (14,3%) | 40 | |
5–6 | 4 (5,6%) | 1 (4%) | 5 | |||||